ALPHA Registry Studies Okami LOBO Vascular Occlusion System

April 8, 2026—Okami Medical announced the enrollment of the first patient in the ALPHA registry, a prospective, multicenter registry evaluating the safety and effectiveness of the company’s LOBO vascular occlusion system for patients with a variety of peripheral vascular conditions, including arterial hemorrhage and pulmonary arteriovenous malformation.

Okami stated that the LOBO device is designed to provide controlled mechanical occlusion of peripheral vessels across a broad range of anatomies. It features an HDBraid construction intended to optimize deliverability, occlusivity, and stability to enable quick and reliable occlusion while maintaining procedural efficiency.

With the ALPHA registry, the company seeks to provide robust evidence on the real-world use of the LOBO device in vascular embolization procedures. The registry will serve as a foundation for the continued expansion of clinical evidence on the LOBO vascular occlusion system, with plans to enroll up to 500 patients across up to 30 sites, noted the press release.

“We are honored to enroll the first patient in the ALPHA registry,” commented Ningcheng “Peter” Li, MD, and Neil J. Resnick, MD, at UMass Memorial Medical Center in Worcester, Massachusetts. “This case demonstrates the utility of the LOBO system in pulmonary arteriovenous malformation (PAVM) treatment.”

They continued, “Multiple PAVMs were treated with LOBO, with one device implanted per feeding artery, and intraprocedural occlusion achieved in under 2 minutes per vessel. This significant milestone kickstarts a substantial effort to generate meaningful clinical evidence supporting the LOBO device.”

Nima Kokabi, MD, site investigator at UNC Health System in Chapel Hill, North Carolina, added in Okami’s press release, “The LOBO vascular occluder is a one-of-a-kind embolization system that delivers fast and predictable occlusion across a wide variety of vascular conditions. The ALPHA registry is uniquely structured to assess distinct outcomes across multiple clinical conditions, with the ability to gather key clinical insights that will help physicians enhance patient care in embolization. We are proud to contribute to the growing body of clinical evidence supporting LOBO and continue to advance this therapy forward.”